Amicus Therapeutics, Inc. Share Price London S.E.
Stocks
0HF9
US03152W1099
Biotechnology & Medical Research
| Market Cap | 454.99Cr 392.02Cr 371.19Cr 336.44Cr 631.19Cr 43TCr 634.39Cr 4.41TCr 1.7TCr 22TCr 1.71TCr 1.67TCr 70TCr | P/E 2024 |
-51.1x | P/E 2025 | -162x |
|---|---|---|---|---|---|
| Enterprise Value | 469.87Cr 404.84Cr 383.33Cr 347.45Cr 651.84Cr 45TCr 655.14Cr 4.55TCr 1.75TCr 23TCr 1.76TCr 1.73TCr 72TCr | EV / Sales 2024 |
5.69x | EV / Sales 2025 | 7.18x |
| Free-Float |
99.31% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript : Amicus Therapeutics, Inc.
| 1 day | +17.93% |
| Manager | Title | Age | Since |
|---|---|---|---|
George Davis
PSD | President | 55 | 27/04/2026 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +17.93% | +18.15% | - | - | 454.99Cr | |
| -0.71% | -6.35% | -2.99% | +9.59% | 4.55TCr | |
| +0.21% | -2.98% | +337.74% | +519.55% | 4.37TCr | |
| +1.74% | -2.24% | +39.82% | +20.76% | 4.31TCr | |
| +1.38% | -3.28% | +6.84% | +67.62% | 3.94TCr | |
| -1.44% | -5.26% | +8.97% | +39.76% | 3.19TCr | |
| +0.87% | -2.60% | - | - | 1.73TCr | |
| +0.75% | -0.64% | +19.75% | +110.17% | 1.64TCr | |
| -0.31% | -2.78% | +10.78% | +31.02% | 1.42TCr | |
| +1.93% | -3.55% | +82.00% | +41.17% | 1.33TCr | |
| Average | +2.24% | -3.57% | +62.86% | +104.96% | 2.94TCr | |
| Weighted average by Cap. | +0.71% | -3.67% | +74.57% | +124.26% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 53Cr 46Cr 43Cr 39Cr 73Cr 5.05TCr 74Cr 511.89Cr 196.84Cr 2.57TCr 198.41Cr 194.05Cr 8.11TCr | 63Cr 55Cr 52Cr 47Cr 88Cr 6.06TCr 88Cr 614.51Cr 236.31Cr 3.08TCr 238.18Cr 232.96Cr 9.74TCr |
| Net income | -5.61Cr -4.83Cr -4.58Cr -4.15Cr -7.78Cr -536.01Cr -7.82Cr -54Cr -21Cr -272.7Cr -21Cr -21Cr -861.7Cr | -2.71Cr -2.34Cr -2.21Cr -2Cr -3.76Cr -259Cr -3.78Cr -26Cr -10Cr -131.77Cr -10Cr -9.96Cr -416.37Cr |
| Net Debt | 19Cr 17Cr 16Cr 14Cr 27Cr 1.85TCr 27Cr 187.68Cr 72Cr 941.45Cr 73Cr 71Cr 2.97TCr | 15Cr 13Cr 12Cr 11Cr 21Cr 1.42TCr 21Cr 144.2Cr 55Cr 723.36Cr 56Cr 55Cr 2.29TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
